2022
Functional and Symptomatic Clinical Trial Endpoints The HFC-ARC Scientific Expert Panel
Psotka M, Abraham W, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Felker G, Jacob R, Kitzman D, Leifer E, Lewis E, Mentz R, Nkulikiyinka R, Ni W, Schaber D, Sharma A, Solomon S, Stockbridge N, Teerlink J, Unger E, Whellan D, Wittes J, Anker S, O'Connor C. Functional and Symptomatic Clinical Trial Endpoints The HFC-ARC Scientific Expert Panel. JACC Heart Failure 2022, 10: 889-901. PMID: 36456063, DOI: 10.1016/j.jchf.2022.09.012.Peer-Reviewed Original ResearchConceptsAcademic Research ConsortiumHeart failureSubmaximal exercise tolerancePatient-reported outcomesCardiovascular clinical researchResearch ConsortiumExercise toleranceScientific Expert PanelPatients' qualityFunctional statusClinical trialsLife endpointsConsensus recommendationsClinical utilityDrug AdministrationCardiovascular therapeuticsClinical researchU.S. FoodExpert panelPotential endpointsNational InstituteEvidence generationTrialsEndpointAcademic investigators
2021
Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure
Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.Peer-Reviewed Original ResearchConceptsEnd-stage heart failureReduced ejection fractionHealth-related qualityPatient-reported health statusEffect of inotropesHeart failureHealth status domainsEjection fractionHealth statusFunctional statusPositive inotropesStatus domainsAvailable clinical trial dataMorbidity/mortalityPopulation of patientsPatient-centered outcomesHealth status outcomesClinical trial dataFunctional capacity changesQuantity of lifeWeb of ScienceInotrope therapyInotrope useCalcium sensitizerSurvival benefit